Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 8, Pages 1972-1979
Publisher
Oxford University Press (OUP)
Online
2013-05-14
DOI
10.1093/annonc/mdt166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
- (2017) A. H. Ko et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603
- (2017) E. M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
- (2017) U. Pelzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy.
- (2017) P. J. Hosein et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic treatment of advanced pancreatic cancer
- (2012) Volker Heinemann et al. CANCER TREATMENT REVIEWS
- Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing
- (2012) C. A. Iacobuzio-Donahue et al. CLINICAL CANCER RESEARCH
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)
- (2012) Volker Heinemann et al. GUT
- Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial
- (2011) Stefano Cereda et al. CHEMOTHERAPY
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
- (2010) Anna Novarino et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
- (2010) Igor A. Astsaturov et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
- (2010) Ourania Katopodis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
- (2010) L. Dahan et al. GUT
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study
- (2009) Brett E. Fortune et al. ONCOLOGY
- Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers
- (2009) Maria S. Pino et al. ONCOLOGY
- Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
- (2009) Joanna M. Brell et al. ONCOLOGY
- Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
- (2009) Roland Andersson et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy
- (2008) M Reni et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses
- (2008) A Sultana et al. BRITISH JOURNAL OF CANCER
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
- (2008) Henry Q. Xiong et al. CANCER
- Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
- (2008) Seong Yoon Yi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
- (2008) Chigusa Morizane et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
- (2008) M. P. Kim et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started